CYP7A1 and metabolic dysfunction-associated steatotic liver disease: In a case-control study, trimethylamine oxide (TMAO), the metabolites from GM, significantly increased BA synthesis by upregulating hepatic CYP7A1 mRNA levels in patients with NAFLD (Tan et al., 2019).